Benzo[g]quinazolines as antifungal against candidiasis: Screening, molecular docking, and QSAR investigations

Abuelizz, 2018, In vitro evaluation of new 2-phenoxy-benzo[g][1,2,4]triazolo[1,5-a]quinazoline derivatives as antimicrobial agents, Microb. Pathog., 117, 60, 10.1016/j.micpath.2018.02.018 Abuelizz, 2020, Investigation of some benzoquinazoline and quinazoline derivatives as novel inhibitors of HCV-NS3/4A protease: Biological, molecular docking and QSAR studies, RSC Adv., 10, 35820, 10.1039/D0RA05604A Abuelizz, 2020, Antiproliferative and Antiangiogenic Properties of New VEGFR-2-Targeting 2-Thioxobenzo [g] Quinazoline Derivatives (In Vitro), Molecules, 25, 5944, 10.3390/molecules25245944 Abuelizz, 2020, Exploiting the 4-Hydrazinobenzoic acid moiety for the development of anticancer agents: Synthesis and biological profile, Bioorg. Chem., 102, 10.1016/j.bioorg.2020.104098 Abuelizz, 2021, In silico study and biological screening of benzoquinazolines as potential antimicrobial agents against methicillin-resistant Staphylococcus aureus, carbapenem-resistant Klebsiella pneumoniae, and fluconazole-resistant Candida albicans, Microb. Pathog., 160, 10.1016/j.micpath.2021.105157 Almehizi, 2019, Investigation the antioxidant activity of benzo[g]triazoloquinazolines correlated with a DFT study, Saudi Pharm. J., 27, 133, 10.1016/j.jsps.2018.09.006 Al-Salahi, 2015, Synthesis and in vitro cytotoxicity evaluation of new 2-thioxo-benzo[g]quinazolin-4(3H)-one derivatives, Heterocycles, 91, 1735, 10.3987/COM-15-13282 Al-Salahi, 2016, Molecular docking study and antiviral evaluation of 2-thioxo-benzo[g]quinazolin-4(3H)-one derivatives, Chem. Cent. J., 10, 2016, 10.1186/s13065-016-0168-x Al-Salahi, 2017, Antimicrobial activity of new 2-thioxo-benzo[g]quinazolin-4(3H)-one derivatives, Med. Chem., 13, 85, 10.2174/1573406412666160610095706 Al-Salahi, R., A Abuelizz, H., Wadi, M., A El Dib, R., A Alotaibi, M., Marzouk, M., 2016. Antimicrobial activity of synthesized 2-methylthiobenzo [g][1, 2, 4]-triazolo [1, 5-a]quinazoline derivatives. Med. Chem. 12, 760–766. Al-Salahi, R., Ahmad, R., Anouar, E., Iwana Nor Azman, N.I., Marzouk, M., Abuelizz, H.A., 2018a. 3-Benzyl (phenethyl)-2-thioxobenzo[g]quinazolines as a new class of potent α-glucosidase inhibitors: synthesis and molecular docking study. Future medicinal chemistry 10, 1889–1905. Al-Salahi, 2018, Radioiodination and biodistribution of newly synthesized 3-benzyl-2-([3-methoxybenzyl] thio) benzo [g] quinazolin-4-(3H)-one in tumor bearing mice, Saudi Pharmaceut. J., 26, 1120, 10.1016/j.jsps.2018.06.001 Al-Salahi, 2019, Anti-HAV evaluation and molecular docking of newly synthesized 3-benzyl (phenethyl) benzo [g] quinazolines, Bioorg. Med. Chem. Lett., 29, 1614, 10.1016/j.bmcl.2019.04.043 Al-Salahi, 2019, Antioxidant activities and molecular docking of 2-thioxobenzo[g]quinazoline derivatives, Pharmacol. Rep., 71, 695, 10.1016/j.pharep.2019.04.003 Andes, 2016, The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET), Transpl. Infect. Dis., 18, 921, 10.1111/tid.12613 Bian, 2017, Synthesis, evaluation and quantitative structure–activity relationship (QSAR) analysis of Wogonin derivatives as cytotoxic agents, Bioorg. Med. Chem. Lett., 27, 1012, 10.1016/j.bmcl.2016.12.076 Chandrika, 2020, Promising antifungal agents: A minireview, Bioorg. Med. Chem., 28 Chen, 2008, A QSAR study and molecular design of benzothiazole derivatives as potent anticancer agents, Sci. China, Ser. B, 51, 111, 10.1007/s11426-007-0107-8 Conti, 2014, Animal models for candidiasis, Curr. Protoc. Immunol., 105, 16, 10.1002/0471142735.im1906s105 Dadar, 2018, Candida albicans-Biology, molecular characterization, pathogenicity, and advances in diagnosis and control–An update, Microb. Pathog., 117, 128, 10.1016/j.micpath.2018.02.028 Devgun, 2021, Molecular docking studies of dihydropyridazin-3 (2H)-one derivatives as Antifungal, antibacterial and anti-helmintic agents, World J. Adv. Res. Rev., 12, 186, 10.30574/wjarr.2021.12.1.0476 Hargrove, 2012, Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Δ7-24, 25-dihydrolanosterol, J. Lipid Res., 53, 311, 10.1194/jlr.M021865 Hargrove, 2017, Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis, J. Biol. Chem., 292, 6728, 10.1074/jbc.M117.778308 Kennard, 1969, Computer aided design of experimental, Technometrics, 11, 137, 10.1080/00401706.1969.10490666 Labute, 2008, The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area, J. Comput. Chem., 29, 1693, 10.1002/jcc.20933 Nobile, 2015, Candida albicans biofilms and human disease, Annu. Rev. Microbiol., 69, 71, 10.1146/annurev-micro-091014-104330 Pfaller, 2011, Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009, Antimicrob. Agents Chemother., 55, 561, 10.1128/AAC.01079-10 Rothstein, 2001, Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5, Antimicrob. Agents Chemother., 45, 1367, 10.1128/AAC.45.5.1367-1373.2001 Stewart, 1989, Optimization of parameters for semiempirical methods I. Method, J. Comput. Chem., 10, 209, 10.1002/jcc.540100208 Takahashi, 2010, Design, synthesis, evaluation and QSAR analysis of N1-substituted norcymserine derivatives as selective butyrylcholinesterase inhibitors, Bioorg. Med. Chem. Lett., 20, 1718, 10.1016/j.bmcl.2010.01.057 Turner, 2014, The Candida pathogenic species complex, Cold Spring Harbor Perspect. Med., 4, 10.1101/cshperspect.a019778 Wayne, P.A., 2009. Clinical and Laboratory Standards Institute.Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline, 2nd ed CLSI document M44-A2 Clinical and Laboratory Standards Institute. Wayne, P.A. 2017. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th ed Approved standard M27 Clinical and Laboratory Standards Institute. Whaley, 2017, Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species, Front. Microbiol., 7, 2173, 10.3389/fmicb.2016.02173 Yousef, 2020, Charge transfer complex of neostigmine with 2, 3-Dichloro-5, 6-dicyano-1, 4-benzoquinone: Synthesis, spectroscopic characterization, antimicrobial activity, and theoretical study, Drug Des. Devel. Ther., 14, 4115, 10.2147/DDDT.S259369